fluorouracil has been researched along with Hepatitis in 4 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Hepatitis: INFLAMMATION of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our purpose was to explore the contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of IFNalpha and 5-fluorouracil (5-FU) combination therapy for hepatocellular carcinoma (HCC)." | 7.72 | Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma. ( Damdinsuren, B; Dono, K; Eguchi, H; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Yagita, H; Yamamoto, T, 2004) |
| "Our purpose was to explore the contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of IFNalpha and 5-fluorouracil (5-FU) combination therapy for hepatocellular carcinoma (HCC)." | 3.72 | Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma. ( Damdinsuren, B; Dono, K; Eguchi, H; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Yagita, H; Yamamoto, T, 2004) |
| "A 69- year-old man with metastatic rectal cancer received 4 courses XELOX therapy." | 1.40 | [A case of metastatic rectal cancer with fulminant hepatitis caused by XELOX therapy]. ( Egawa, T; Ito, Y; Kemmochi, T; Makino, H; Nagashima, A; Ohkubo, Y; Shimokawa, R; Suzuki, Y; Yamamuro, W; Yoneda, M, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kemmochi, T | 1 |
| Suzuki, Y | 1 |
| Yoneda, M | 1 |
| Ito, Y | 1 |
| Ohkubo, Y | 1 |
| Egawa, T | 1 |
| Nagashima, A | 1 |
| Shimokawa, R | 1 |
| Makino, H | 1 |
| Yamamuro, W | 1 |
| Barnett, KT | 1 |
| Malafa, MP | 1 |
| Yamamoto, T | 1 |
| Nagano, H | 1 |
| Sakon, M | 1 |
| Wada, H | 2 |
| Eguchi, H | 1 |
| Kondo, M | 1 |
| Damdinsuren, B | 1 |
| Ota, H | 1 |
| Nakamura, M | 1 |
| Marubashi, S | 1 |
| Miyamoto, A | 1 |
| Dono, K | 1 |
| Umeshita, K | 1 |
| Nakamori, S | 1 |
| Yagita, H | 1 |
| Monden, M | 1 |
| Markoff, N | 1 |
2 reviews available for fluorouracil and Hepatitis
| Article | Year |
|---|---|
Complications of hepatic artery infusion: a review of 4580 reported cases.
Topics: Antimetabolites, Antineoplastic; Arterial Occlusive Diseases; Bone Marrow Diseases; Catheters, Indwe | 2001 |
[Long-term therapy of liver diseases].
Topics: Aged; Anabolic Agents; Chronic Disease; Cortisone; Diet Therapy; Fatty Liver; Female; Fluorouracil; | 1972 |
2 other studies available for fluorouracil and Hepatitis
| Article | Year |
|---|---|
[A case of metastatic rectal cancer with fulminant hepatitis caused by XELOX therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Hep | 2014 |
Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis | 2004 |